Investors

Media Room

In The News

May 27, 2022

AREV Life Sciences issues retention warrants

April 21, 2022

AREV Life Sciences Global Corporation announces engagement of TransBIOTech to facilitate preclinical therapeutic pipeline development

April 19, 2022

Brian V. Elliott Joins Arev Life Sciences Global Corporation

April 8, 2022

Kevin Phelps, CPA Appointed Chief Operating Officer of Arev Life Sciences Global Corporation & Warrant Offering

March 10, 2022

AREV Life Sciences enters Into Collaboration Agreement with Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba

February 23, 2022

AREV Life Sciences Completes Lab and Fungi Fruiting Room Build

February 17, 2022

AREV Life Sciences Advances Developments, New Appointments, and Relationships

January 18, 2022

AREV SAB member Richard Van Breeman PhD publishes landmark study on CoVid19

December 23, 2021

AREV Life Sciences appoints Allan Echino as Director and Denby Greenslade as interim CFO

December 9, 2021

AREV Life Sciences Settles Pending Litigation with Harvey

December 2, 2021

AREV Life Sciences / Absolem JV Receives Extraction Results

November 30, 2021

AREV Acquires Wright & Well Essentials Inc

November 8, 2021

AREV LIFE SCIENCES GLOBAL CORP ANNOUNCES STOCK OPTION GRANT

September 7, 2021

AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB REVISED RELEASE first issued July 28, 2021

September 2, 2021

AREV Announces Brian Cameron as Chief Financial Officer

August 13, 2021

AREV Changes their name to AREV Life Sciences Global Corp

July 29, 2021

AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB

July 22, 2021

Data Presented at the 11th IAS Conference on HIV Science Supports AREV’s Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation

July 6, 2021

AREV Expands Operations to Rochester New York Establishing Wholly Owned U.S. Subsidiary, AREV Life Sciences, Inc.

June 10, 2021

AREV CEO Michael Withrow Buys 900,000 Shares of Company Stock

Press Releases

June 12, 2023

NOTICE OF DEFAULT - UPDATE

May 29, 2023

NOTICE OF DEFAULT - UPDATE

May 15, 2023

NOTICE OF DEFAULT - UPDATE

May 9, 2023

AREV IMPLEMENTS AI AS A DRIVING FORCE TO IDENTIFY SCIENCE BACKED COMPOUNDS SYNERGISTIC TO ITS PROPRIETARY EXTRACTS TO INCREASE EFFICACY OF TRADITIONAL MEDICINE

April 27, 2023

AREV Life Sciences Global Corp. Announces Filing of Application for Management Cease Trade Order

March 27, 2023

AREV TERMINATES PRIVATE PLACEMENT AND TERM SHEET WITH FIBERLAB, Inc.

March 15, 2023

AREV Signs Term Sheet with Fiberlab, Inc.

February 28, 2023

AREV Life Sciences Provides Annual Review for 2022 and Operational Update

February 15, 2023

TEAM FROM QUEENSLAND BRAIN INSTITUTE IDENTIFIES NEW HERICERIN DERIVITIVES FROM LIONS MANE THAT BOOST NERVE GROWTH AND ENHANCES MEMORY

January 4, 2023

AREV Annual General Meeting Results - January 2023

January 6, 2023

Arev Board Change

January 12, 2023

AREV ISSUES INCENTIVE STOCK OPTIONS

November 8, 2022

AREV SIGNS TERM SHEET WITH SALT SPRING ISLAND BOTANAMED

October 28, 2022

Dr. Andrew Levinson Joins AREV Life Sciences Global Corporation Scientific Advisory Board

September 22, 2022

AREV NOTES U.S. GOVERNMENTS $2.9 BILLION ASSISTANCE TO ADDRESS FOOD INSECURITY

August 25, 2022

SUSTAINN, AREV’s Ready to Use Therapeutic Foods discussed in leading article in HealthHIV

August 17, 2022

AREV ADDS DR. APTE TO THE SAB

August 17, 2022

AREV CORPORATE UPDATE

August 10, 2022

AREV CORPORATE UPDATE

June 15, 2022

AREV Life Sciences announces acceleration of the clinical development of SUSTAINN, as further predictions of global famine increase demand for Ready to Use Therapeutic Foods (RUTF’s)

Peer Reviewed Articles

May 28, 2021

The protective effect of eicosapentaenoic acid-enriched phospholipids from sea cucumber...

May 28, 2021

Medicinal and health benefit effects of functional sea cucumbers